Cargando…
Kinetics of Blood–Brain Barrier Transport of Monoclonal Antibodies Targeting the Insulin Receptor and the Transferrin Receptor
Biologic drugs are large molecule pharmaceuticals that do not cross the blood–brain barrier (BBB), which is formed by the brain capillary endothelium. Biologics can be re-engineered for BBB transport as IgG fusion proteins, where the IgG domain is a monoclonal antibody (MAb) that targets an endogeno...
Autor principal: | Pardridge, William M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8778919/ https://www.ncbi.nlm.nih.gov/pubmed/35056060 http://dx.doi.org/10.3390/ph15010003 |
Ejemplares similares
-
Mathematical Models of Blood-Brain Barrier Transport of Monoclonal Antibodies Targeting the Transferrin Receptor and the Insulin Receptor
por: Pardridge, William M., et al.
Publicado: (2021) -
Blood–Brain Barrier Transport of Transferrin Receptor-Targeted Nanoparticles
por: Thomsen, Maj Schneider, et al.
Publicado: (2022) -
Receptor-mediated drug delivery of bispecific therapeutic antibodies through the blood-brain barrier
por: Pardridge, William M.
Publicado: (2023) -
Treatment of Parkinson’s disease with biologics that penetrate the blood–brain barrier via receptor-mediated transport
por: Pardridge, William M.
Publicado: (2023) -
Pharmacokinetics and Safety in Rhesus Monkeys of a Monoclonal Antibody-GDNF Fusion Protein for Targeted Blood-Brain Barrier Delivery
por: Pardridge, William M., et al.
Publicado: (2009)